Active substances
Fluticasone + Umeclidinium + Vilanterol
- SFDA 1
- Health Canada 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA 100/62.5/25MCG Inhalation powder, pre-dispensed | 100,62.5,25 µg,µg,µg | Inhalation powder, pre-dispensed · Inhalation use | 1 Inhaler | SAR 236.80 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TRELEGY ELLIPTA | 02474522 | 62.5 MCG / ACT; 25 MCG / ACT; 100 MCG / ACT | POWDER · INHALATION | GLAXOSMITHKLINE INC |
| TRELEGY ELLIPTA | 02515776 | 25 MCG / ACT; 200 MCG / ACT; 62.5 MCG / ACT | POWDER · INHALATION | GLAXOSMITHKLINE INC |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.